The primary objective of the ongoing trial is to determine whether ambrisentan can prevent the progression to respiratory failure and reduce the need for mechanical ventilation, among others
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Theradaptive's regenerative implants are best-in-class and are designed to permit precise tissue regeneration for a variety of tissue types and clinical indications
Launching in 2022, its availability will be expanded to the global market
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Subscribe To Our Newsletter & Stay Updated
